Helping melanoma patients decide whether to choose adjuvant high-dose interferon-α2b

Oncologist

Volumn 10, Issue 9, 2005, Pages 739-742

  Hurley, Karen E ^a   Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant treatment; Interferon; Melanoma; Risk benefit; Survival

Indexed keywords

ALPHA2B INTERFERON; DACARBAZINE; PEGINTERFERON;

ARTICLE; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; DECISION MAKING; DEPRESSION; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; LIVER TOXICITY; MELANOMA; MYALGIA; ONCOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUICIDAL BEHAVIOR; SURVIVAL RATE;

DECISION MAKING; HUMANS; INTERFERON ALFA-2B; MELANOMA;

EID: 27644510419     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-9-739     Document Type: Article

References (13)

1. Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444-2458.
2. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
3. Kirkwood JM, Manola J, Ibrahim J et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-1677.
4. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-966.
5. Capuron L, Ravaud A, Miller AH et al. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 2004;18:205-213.
6. Trask PC, Paterson AG, Esper P et al. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology 2004;13:526-536.
7. Kilbridge KL, Weeks JC, Sober AJ et al. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 2001;19:812-823.
8. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
9. Kilbridge KL, Cole BF, Kirkwood JM et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol 2002;20:1311-1318.
10. Jansen SJ, Otten W, Stiggelbout AM. Review of determinants of patients' preferences for adjuvant therapy in cancer. J Clin Oncol 2004;22: 3181-3190.
11. Borgen PI, Hill AD, Tran KN et al. Patient regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 1998;5:603-606.
12. Frost MH, Schaid DJ, Sellers TA et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 2000;284:319-324.
13. Capuron L, Gumnick JF, Musselman DL et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002;26:643-652.